Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

271.99 +46.45 (+20.60%)
Streaming Delayed Price Updated: 11:52 AM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
What Does the Market Think About Penumbra?
 
Via Benzinga
PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance
Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue... 
Via StockStory
Expert Outlook: Penumbra Through The Eyes Of 7 Analysts
 
Via Benzinga
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Peering Into Penumbra's Recent Short Interest
 
Via Benzinga
What's Driving the Market Sentiment Around Penumbra?
 
Via Benzinga
1 Safe-and-Steady Stock with Promising Prospects and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Penumbra PEN Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
3 Cash-Producing Stocks Walking a Fine Line
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Penumbra (PEN) Q2 Revenue Jumps 13%
Via The Motley Fool
Penumbra (PEN) Shares Skyrocket, What You Need To Know
Shares of medical device company Penumbra (NYSE:PEN) jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and... 
Via StockStory
Topics ETFs Stocks World Trade
Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Penumbra’s (NYSE:PEN) Q2: Strong Sales, Stock Soars
Medical device company Penumbra (NYSE:PEN) announced better-than-expected revenue in Q2 CY2025, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue guidance of $1.36... 
Via StockStory
Penumbra Inc (NYSE:PEN) Surpasses Q2 2025 Earnings and Revenue Estimates Amid Market Challenges
Penumbra Inc (NYSE:PEN) beat Q2 2025 revenue and EPS estimates, reporting $339.46M and $0.86, driven by strong demand for its thrombectomy and vascular intervention tech. 
Via Chartmill
Penumbra (PEN) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Penumbra (NYSE:PEN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
3 Profitable Stocks Walking a Fine Line
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
PENUMBRA INC (NYSE:PEN) – A Strong Growth Stock with Technical Breakout Potential
PENUMBRA INC (NYSE:PEN) is a strong growth stock with solid fundamentals and a promising technical setup. The company shows robust revenue growth, financial health, and breakout potential. 
Via Chartmill
Winners And Losers Of Q1: Penumbra (NYSE:PEN) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Let’s dig into the relative performance of Penumbra (NYSE:PEN) and its peers as we unravel the now-completed Q1 medical devices & supplies - cardiology, neurology, vascular earnings season. 
Via StockStory
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
PENUMBRA INC (NYSE:PEN) – A Strong Growth Stock with Technical Breakout Potential
PENUMBRA INC (NYSE:PEN) is a strong growth stock with a bullish technical setup, supported by solid revenue and earnings growth. The company's financial health and breakout potential make it an... 
Via Chartmill
1 High-Flying Stock on Our Buy List and 2 to Avoid
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
PEN Q1 Earnings Call: U.S. Thrombectomy Drives Outperformance as International Headwinds Persist
Medical device company Penumbra (NYSE:PEN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 16.3% year on year to $324.1 million. The company expects the full year’s revenue to be... 
Via StockStory
Topics World Trade
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. 
Via MarketBeat
Topics Economy
3 Profitable Stocks in the Doghouse
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.